This poster, presented at MDA 2024, explores the use of ataluren to prevent ambulatory decline in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This poster, presented at MDA 2024, provides insights into the demographics of young patients with Duchenne muscular dystrophy (DMD) who are receiving deflazacort in the US
The PTC Therapeutics symposium at MDA 2023 focused on all-around care for Duchenne muscular dystrophy (DMD). This symposium detailed how corticosteroids can be integrated into all-around DMD care
The PTC Therapeutics symposium at MDA 2023 focused on all-around care for Duchenne muscular dystrophy (DMD). This infographic, distributed during the symposium, provides a summary of how corticosteroids can be integrated into all-around DMD care
This poster, presented at MDA 2023, provides an overview of a phase 3 placebo-controlled trial assessing the motor function of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) treated with ataluren
This poster, presented at MDA 2023, assesses the efficacy of ataluren on muscle function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) over 3 trials
This poster, presented at MDA 2023, provides an overview of a phase 3 trial assessing the effects of ataluren on muscle burst activity in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Year
Therapy area
Congress
Type
Topic